Browsing Tag
Facioscapulohumeral muscular dystrophy
2 posts
Why Novartis’ $12bn Avidity bet suddenly looks more interesting after new del-brax data
Find out how Novartis AG’s del-brax data could strengthen its $12bn Avidity Biosciences bet and rare muscle disease strategy.
Facioscapulohumeral muscular dystrophy market is set to expand through 2034 with gene therapy innovation and FDA acceleration
Facioscapulohumeral muscular dystrophy market to expand across 7MM by 2034, driven by gene therapy, rising diagnosis, and key drug launches from Roche, Avidity, and Epicrispr.